Oxford Nanopore Targets $700M Revenue by 2030 in Profitability Push

Key Facts

In a strategic move to define its long-term growth trajectory, Oxford Nanopore Technologies has unveiled ambitious financial targets through the end of the decade. According to reports, the DNA-sequencing specialist is targeting annual revenue exceeding $700 million by 2030, with a longer-term ambition to surpass the $1 billion mark. This roadmap is part of a new strategy under its leadership focused on biopharma, clinical testing, and research sectors.

Financial results show the company's revenue for the first half of 2026 rose 10.5% to £116.7 million, driven by a 35.4% surge in clinical sales. The reported loss for the period narrowed significantly to £48 million from £71.8 million a year earlier, while gross margins expanded by 4 percentage points to 62.2%. Furthermore, the company secured a post-period cross-licensing deal worth $20 million this year, bolstered by committed product purchases.

Looking ahead, Oxford Nanopore expects to break even on adjusted earnings in 2027 and achieve positive free cash flow by 2028. As of August 19, 2026, specific market price levels for the instrument are unavailable in the current data snapshot, requiring investors to focus on qualitative growth indicators and the company's cash position of £234.5 million. Market participants should also note broader UK economic context, where recent data showed annual GDP growth at 1.2%.